(Q43711552)

English

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

scientific article published on 10 December 2012

Statements

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. (English)
0 references
0 references
Jesús F San Miguel
Rudolf Schlag
Martin Kropff
Bin Jiang
Kevin Liu
10 December 2012
448-455

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit